Answer from: Radiation Oncologist at Academic Institution
In an older person with poor PS who is not symptomatic from the leptomeningeal disease, they are still more likely to suffer from their primary tumor so I think it is reasonable to just ignore it.
I think performance status and prognosis (age, MGMT) are critical. One could argue for a tri...
I'd be eager to hear from other neuro-oncologists on this but generally, in my practice, similar to without LMD. Our chemotherapeutic agents are BBB penetrants, and IT cytotoxic chemotherapy only penetrates a couple of millimeters (so would not address the parenchymal disease). Having said this, I'm...
Answer from: Radiation Oncologist at Academic Institution
Considered initially a rare complication in gliomas, the incidence of LMD is estimated at 4%, reaching 25% on postmortem neuropathological evaluation. There is no standard-of-care treatment for LMS in patients with GBM, although multiple groups have proposed several therapeutic options (e.g., methot...